International Journal of Pharmaceutical research and Applications
Volume 11, Issue 1, Jan - Feb 2026, pp:62-66 www.ijprajournal.com ISSN: 2456-4494

# Regulatory Framework and Global Perspectives on Radiopharmaceuticals

Aditya Jain, Vipin Mathur*
*Lachoo Memorial College of Science & Technology (Autonomous), Sector - A, Shastri Nagar, Jodhpur*
*Address for correspondence: Dr. Vipin Mathur, Associate Professor, Lachoo Memorial College of Science & Technology (Autonomous), Sector – A, Shastri Nagar, Jodhpur*

Date of Submission: 02-01-2026 Date of acceptance: 10-01-2026

## ABSTRACT
Radiopharmaceuticals represent a distinct class of medicinal products that integrate radioactive isotopes with biological targeting vectors to enable disease visualization and targeted radiation therapy. Their dual functionality has led to major advances in precision medicine, particularly in oncology, cardiology, and neurology. As innovation accelerates, regulatory bodies face the challenge of ensuring patient safety, manufacturing quality, and reliable supply while supporting scientific progress. This review provides an overview of the development, therapeutic significance, regulatory approaches, and future considerations governing radiopharmaceuticals, with emphasis on international systems and the Indian regulatory model.

**Keywords:** Radiopharmaceuticals; Theranostics; Targeted radionuclide therapy; Regulatory framework; Nuclear medicine

## I. INTRODUCTION
Radiopharmaceuticals are important compounds of medicine, chemistry, and nuclear physics. They are unique therapeutic and diagnostic agents formed by linking radioisotopes to biologically active molecules such as peptides, or antibodies that guide the radionuclide to specific cellular targets within the human body.This design enables visualization of molecular processes or destruction of diseased tissues through ionizing radiation, placing radiopharmaceuticals at the core of precision healthcare [1]. Their application spans early disease detection, staging, treatment monitoring, and personalized therapy, consolidating their role in contemporary clinical practice [2].

## II. CLINICAL APPLICATIONS AND THERANOSTIC ADVANCEMENTS
Radiopharmaceuticals serve two complementary purposes in modern medicine i.e. Diagnostics and Therapeutics.

- Diagnostic utility: They form an important part of modern imaging techniques like Positron Emission Tomography (PET), Single-Photon Emission Computed Tomography, (SPECT), and hybrid systems such as PET/CT enables three-dimensional visualization of physiological processes, improving diagnostic accuracy and guiding treatment decisions across multiple disease states [3].These agents allow to view non-invasively biological functions at a molecular level and thus help in the quantification and monitoring of disease lesions. That is important in early disease diagnosis, correct staging, and treatment planning-especially in neurologies and oncologies. Radiopharmaceuticals for diagnosis allow the medical professional to "see" a disease before treatment and enable personalized treatment approaches.Diagnostic applications account for the vast majority of radiopharmaceutical use and support early detection and staging of malignancies, neurodegenerative diseases, and cardiac disorders [4].
- Targeted radionuclide therapy (TRT): It is also referred as Radiopharmaceutical therapy. It utilizes radiopharmaceuticals to precisely deliver a high-energy dose of cytotoxicradiation to pathological tissues, such as tumors. By this it minimizes off-target exposure and reduces systemic toxicities associated with external beam radiotherapy [5]. TRT leverages beta- or alpha-emitting isotopes to induce DNA strand breaks within cancer cells, improving outcomes in advanced malignancies such as neuroendocrine tumors and prostate cancer [6].
- Theranostics: The most advanced application of radiopharmaceuticals is the radiotheranostic approach, which is the synergistic combination of a diagnostic agent and its corresponding therapeutic agent. This facilitate a seamless transition from diagnosis to targeted therapy. Examples like the ^68Ga/^177Lu-labeled

International Journal of Pharmaceutical research and Applications
Volume 11, Issue 1, Jan - Feb 2026, pp:62-66 www.ijprajournal.com ISSN: 2456-4494

DOTA-TATE and PSMA-targeted ligands have demonstrated remarkable efficacy in treating refractory and metastatic cancers [7].

## III. Pharmacokinetic and Mechanistic Considerations

The effectiveness of radiopharmaceuticals depends largely on their pharmacokinetic behavior, encompassing molecular transport, receptor affinity, metabolism, and clearance [8]. Investigators continue to optimize chemical composition and molecular targeting strategies to increase specificity and therapeutic potential. Key findings pertain to the development of new targeting agents and novel delivery systems that enhance safety and efficacy.

From the first use of radioisotopes in cancer treatment, more than 60 radiopharmaceuticals have been approved for cancers, neurodegenerative disorders, and cardiovascular diseases. Ongoing refinement and application of these compounds are promising to unlock new opportunities for personalized medicine and set new standards in the detection and treatment of diseases, improving patient outcomes [9].

## IV. HISTORICAL FOUNDATIONS

The practice of nuclear medicine and the use of radiopharmaceuticals - agents that provide unique physiological data for diagnosis and deliver targeted radiation for therapy - is a story spanning over a century, built upon foundational scientific discoveries.

4.1 The Dawn of Radioactivity and Medical Tracers (Late 19th - Early 20th Century):
The historical roots of radiopharmaceuticals lie in the foundational discoveries of the late 19th and early 20th centuries:

- Discovery of Radioactivity (1896): Henri Becquerel's accidental discovery that uranium salts emitted penetrating rays set the stage for understanding natural radioactivity.
- Pioneering Elements: Marie and Pierre Curie extended this work by discovering and characterizing new, highly radioactive elements, radium and polonium, establishing the fundamental principles of radioactivity and hinting at its potential medical utility [10].
- The First Tracer (1913): Georg de Hevesy conducted the first recorded experiment using a radioactive isotope, lead-212, as a tracer to study lead absorption in plants. This established the crucial concept of using radioisotopes to track and study processes within biological systems.

4.2 Establishing Clinical Use (Mid-20th Century)
The transition from scientific curiosity to clinical practice began in the 1930s:

- First Human Use (1936): The field formally entered the clinic with the use of 24Na-sodium chloride by Hamilton and Stone.
- Thyroid Therapy: The therapeutic application of 131I-iodide quickly became established for treating thyroid disease, making radionuclide imaging a routine procedure in hospitals [11].

4.3 The Rise of Modern Nuclear Medicine
The field saw explosive growth and accessibility with the introduction of a new, versatile isotope:

- The Staple Radionuclide: The development and widespread availability of a range of 99mTc-radiotracers cemented its position as the staple medical radionuclide. Critically, these could be easily and quickly synthesized in hospitals using simple kit vials, democratizing access to diagnostic nuclear medicine.
- Growth in Applications: This accessibility fueled the growth of both diagnostic and therapeutic nuclear medicine, leading to the estimated 20 million diagnostic nuclear medicine procedures performed annually in the US today. Diagnostic imaging provides unique physiologic temporal and spatial information visualized by planar imaging, SPECT, and PET.
- Modern Fusion Imaging: Modern technology has advanced to fuse the physiological data from SPECT or PET with the high-resolution anatomical data from CT or MRI, providing enhanced clinical information particularly beneficial in oncology, cardiology, endocrinology, and neurology.

The continuous expansion and success of radiopharmaceuticals have been—and remain—dependent on the close, innovative cooperation among clinicians, physicists, engineers, biologists, and chemists.

## V. REGULATORY FRAMEWORK FOR RADIOPHARMACEUTICALS IN INDIA

The regulation of radiopharmaceuticals in India is a collaborative process involving two key government authorities, reflecting the dual nature of these agents as both radioactive substances and pharmaceutical drugs.

Key Regulatory Authorities: The primary oversight for radiopharmaceuticals in India is shared between the Atomic Energy Regulatory Board (AERB) and the Central Drug Standard Control Organization (CDSCO).

(i) Atomic Energy Regulatory Board (AERB):

- Role and Mandate: Established in November 1983 under the Department of Atomic Energy (DAE), the AERB is the paramount authority responsible for enforcing regulatory and safety measures under the Atomic Energy Act, 1962.
- Scope: Its primary focus is on the safe handling, use, and disposal of radioactive materials, ensuring protection against nuclear radiation risks for the public and the environment. This includes regulating the production, supply, and use of all radioactive substances, which is critical for radiopharmaceuticals [12].
- Support: The Bhabha Atomic Research Centre (BARC), a major DAE research institution, actively supports the medical applications and oversight of radioactive substances.

(ii) Central Drug Standard Control Organization (CDSCO):

- Role and Mandate: Operating under the Ministry of Health and Family Welfare, the CDSCO is responsible for regulating drugs and cosmetics in the country.
- Scope: It enforces the Drug and Cosmetic Act of 1940 and its associated rules. The CDSCO's role is to ensure the quality, efficacy, and safety of radiopharmaceuticals as medicinal products. This involves procedures related to drug approval, manufacturing standards, and clinical trials [13].

While India has an established regulatory system, the rapid advancements in nuclear medicine and the growing use of theranostics - the combination of diagnostic and therapeutic radiopharmaceuticals—demand a continually evolving framework.

- Need for Modernization: India's regulatory bodies are recognized as needing to strengthen and harmonize their guidelines with international standards. This includes adopting best practices such as: Good Manufacturing Practices (GMP); Good Laboratory Practices (GLP); Good Regulatory Practices (GRP) and Ethical standards like the Declaration of Helsinki.
- Emerging Challenges: The increasing complexity of new radiopharmaceuticals and the integration of technologies like artificial intelligence (AI) in their development and use necessitates a considerable up-gradation in the existing regulations and guidelines for clinical use and evaluation.

In essence, India's regulatory landscape for radiopharmaceuticals is currently anchored by the AERB for radiation safety and the CDSCO for drug quality, with an ongoing need for a modern, collaborative approach to integrate these mandates and align with global advancements.

## VI. GLOBAL REGULATORY LANDSCAPE AND MARKET DYNAMICS

The factors such as an aging population and increased prevalence of cardiovascular, oncological, and neurological disorders are driving up the global radiopharmaceuticals market. This growth is anticipated to be further driven by the shift from sole diagnostic use to expanded therapeutic applications, and regulation regarding radiopharmaceuticals for the paediatric population has been put in place.

Market Growth and Regional Dominance

The global radiopharmaceutical market is witnessing rapid growth, and strong growth is forecasted in major regions:

- Market Growth Rate: The market was expected to grow at a rapid pace, at a CAGR of 18.30% from 2012 to 2018.
- North America Lead: The North American region commanded over 40% market share in 2016 and is likely to breach $4,000 million by 2026, at a CAGR of 6.2%. The domination of this region can be attributed to the presence of highly advanced SPECT and PET scanning machines, continuous technology update, and high accessibility to SPECT and PET modalities.
- Asia Pacific Expansion: The Asia Pacific is expected to be the fastest-growing regional market in terms of revenue, at a CAGR of 6.3%. Japan continues to dominate the market for diagnostic radioisotopes, with around 40% share.
- European Market: The European market is also growing at a considerable rate, which is projected to reach a value of $1.62 billion by 2020 at a CAGR of 8.2%.

The major players functioning in this market include Bayer Healthcare AG, Cardinal Health, GE Healthcare, and Siemens Healthcare, among others.

The growth potential of the market indicates that regulatory bodies across the globe need to reconsider their frameworks in order to accommodate new products with ease and speed.

## VII. KEY REGULATORY CHALLENGES AND OVERSIGHT

Radiopharmaceutical production and use are highly technical and tightly regulated because radiopharmaceuticals possess the dual identity of pharmaceutical drugs combined with radioactive materials.

7.1 Regulatory Bodies and Standards

- International Oversight: The international bodies like the International Atomic Energy Agency take center stage in the development of safety standards and technical guidance. The European Medicines Agency oversees quality, safety, and efficacy for the European market.
  US Regulation (FDA/NRC): Within the US, the FDA's Center for Drug Evaluation and Research, or CDER, oversees New Drug Application. Regulations are vast in number and include:
- National Oversight: National agencies like the MHRA are responsible for enforcing country-specific regulations, such as those in the UK.

7.2 The Challenge of Short Half-Lives:

A particular challenge, specific to the manufacture of radiopharmaceuticals, is the short half-life of many radionuclides. Fluorine-18, for example, which is used in PET imaging, has a half-life of roughly 110 minutes.

This inherent instability forces manufacturers to complete the entire process of production, testing, and delivery to the patient within a very small time frame, often only a few hours. This, in turn, imposes heavy logistical challenges during manufacturing and distribution, especially over large geographic areas.

## VIII. CLINICAL IMPACT AND SCIENTIFIC MOMENTUM

The core value of radiopharmaceuticals indeed lies in the dual functionality: diagnosis, by way of SPECT/PET imaging, and Targeted Radionuclide Therapy. This is fully realized in the radiotheranostic paradigm that pairs diagnostic and therapeutic agents for personalized, seamless care-a significant advantage compared to conventional modalities. Continuous research, especially refining pharmacokinetics and developing new molecular targeting strategies, is realizing new potential, as more than 60 approved radiopharmaceuticals exist for a variety of conditions. It truly represents a century of collaborative scientific effort driving clinical breakthroughs, from the foundational discoveries of Becquerel and the Curies to the standardization of 99mTc-radiotracers.

### 8.1 Global Market and Unique Operational Challenges

The global radiopharmaceuticals market is at the crossroads of exponential growth due to increasing population age and rising incidence of oncological and cardiovascular pathologies. Advanced infrastructure and access ensure that regions like North America lead, while the Asia Pacific region is emerging as a high-growth area. This growth has presented a very special operational challenge: most of the radionuclides being used-for instance, Fluorine-18-have very short half-lives. This intrinsic instability thus puts extremely tight logistical constraints on manufacturing, testing, and delivery; hence, efficient supply chain management is of greatest importance, ultimately reinforcing the need for regulatory approval.

### 8.2 The Imperative for Harmonized Regulation

Governance of radiopharmaceuticals demands sound regulatory frameworks to handle the risks due to radioactivity, besides pharmaceutical quality, efficacy, and safety.

- Global Oversight: International entities, such as the IAEA, and regional bodies like the EMA and US FDA-in concert with the NRC-have established strict guidelines, including cGMP and specific application processes, by which to regulate the entire lifecycle of the products [14].
- Indian Context: In India, regulatory oversight is divided between the Atomic Energy Regulatory Board (AERB) that administers radiation safety under the Atomic Energy Act and the Central Drug Standard Control Organisation (CDSCO) that enforces drug quality under the Drugs and Cosmetic Act.
- Need for Modernization: The Indian regulatory framework essentially needs urgent modernization to fully capitalize on global advancements in nuclear medicine and complex new products that will be introduced, some of which will employ Artificial Intelligence.

Harmonization with international standards like GMP, GLP, and GRP is important to facilitate seamless market entry for innovative radiopharmaceuticals that will improve patient care and outcomes

## IX. CONCLUSION

Radiopharmaceuticals represent a dynamic and essential domain within modern healthcare, integrating principles from medicine, chemistry, and nuclear physics, enabling both very precise diagnostics and targeted therapeutics. The evidence presented in this review underlines the deep clinical utility of these agents, their long and innovative history, the burgeoning global market, and the critical need for a responsive regulatory environment.

In summary, radiopharmaceuticals stand out as a tribute to scientific ingenuity and a game-changing tool for precision medicine. Whether this momentum is maintained and their full therapeutic potential is reached depends on the ongoing innovation from the scientific community and the dedication of global and national regulators to continuing to adjust their frameworks in ways that are both strict yet responsive to technological advancements.

## REFERENCES

[1]. Wernick MN, Aarsvold JN. *Emission Tomography: The Fundamentals of PET and SPECT.* Academic Press; 2004.

[2]. Torres L, Erdi YE. Nuclear medicine in personalized oncology. *Front Oncol.* 2020;10:995.

[3]. Cherry SR, Sorenson JA, Phelps ME. *Physics in Nuclear Medicine.* 4th ed. Elsevier; 2012.

[4]. Werner RA, Higuchi T, Javadi MS, Hasselmann N, et al. Radiopharmaceuticals in preclinical and clinical development. *J Nucl Med.* 2019;60(6):829-842.

[5]. Price EW, Orvig C. Matching chelators to radiometals for radiopharmaceuticals. *Chem Soc Rev.* 2014;43(1):260-290.

[6]. Sgouros G, Bodei L, McDevitt MR, Nedrow JR. Radiopharmaceutical therapy in cancer. *J Nucl Med.* 2020;61(5):685-692.

[7]. Herrmann K, Schwaiger M, Lewis JS, Baum RP. Radiotheranostics: a roadmap for future development. *Lancet Oncol.* 2020;21(3):e146-e156.

[8]. Saha GB. *Fundamentals of Nuclear Pharmacy.* 7th ed. Springer; 2018.

[9]. Gill MR, Falzone N, Du Y, Vallis KA. Targeted radionuclide therapy in oncology. *Lancet Oncol.* 2017;18(6):e414-e423.

[10]. Curie M. *Radioactive Substances.* Academic Press; 1904.

[11]. Kowalsky RJ, Falen SW. *Radiopharmaceuticals in Nuclear Pharmacy and Nuclear Medicine.* 4th ed. Amer Pharmacists Assoc; 2020.

[12]. Atomic Energy Regulatory Board (AERB). *Safety Code on Nuclear Medicine Facilities, AERB/SC/MED-5.* Mumbai: AERB; 2011.

[13]. Central Drugs Standard Control Organisation (CDSCO). *Guidance for Industry: Radiopharmaceuticals.* Ministry of Health and Family Welfare; 2021.

[14]. European Medicines Agency (EMA). *Guideline on Radiopharmaceuticals.* EMA/CHMP; 2008.